Serina Therapeutics, Inc. (SER) director Simon Farrell files Form 3

Rhea-AI Filing Summary

Serina Therapeutics, Inc. reported a Form 3 insider filing for director Simon Farrell. This initial insider report shows no listed buy, sell, acquisition, disposition, option exercise, gift, or derivative transactions, and the structured data includes no reported current derivative positions or holding entries for this reporting person.

Key Terms

Form 3, insider filing, reporting person

3 terms

Form 3 regulatory

"INSIDER FILING DATA (Form 3)"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

insider filing regulatory

"INSIDER FILING DATA (Form 3)"

reporting person regulatory

""reportingPersons": [ { "name": "Simon Farrell""

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding Insider Trading Forms →

Available on EDGAR 07/23/2026 - 06:49 PM Accepted by SEC EDGAR 07/23/2026 - 06:49 PM Learn about SEC filing dates

FAQ

What does the Form 3 for Serina Therapeutics (SER) show?

The Form 3 for Serina Therapeutics (SER) identifies Simon Farrell as a director and reporting person. The structured data lists no buy, sell, acquisition, disposition, option exercise, gift, or derivative transactions and no reported current holdings in this insider filing.

Who is the reporting person in Serina Therapeutics (SER)'s Form 3?

The reporting person is Simon Farrell, identified in the data as a director of Serina Therapeutics, Inc. He is not flagged as an officer or ten percent owner, and this Form 3 records his status as a reporting insider for the company.

Does the Serina Therapeutics (SER) Form 3 indicate any insider buying or selling?

No. The Form 3 data for Serina Therapeutics (SER) shows zero buy transactions, zero sell transactions, and no derivative exercises, gifts, or restructurings. It therefore provides no evidence of insider share purchases or sales by the reporting person in this report.

Are any derivative securities reported in the Serina Therapeutics (SER) Form 3?

The Form 3 for Serina Therapeutics (SER) lists no derivative transactions and an empty derivativeSummary, indicating that no options, warrants, or other derivative positions are reported for Simon Farrell in this particular insider ownership filing.

What does the transaction summary in SER's Form 3 reveal?

The transactionSummary shows zero buy, sell, acquisition, disposition, exercise, gift, or restructuring transactions and zero holding entries. This means the Form 3 functions primarily as an identification of Simon Farrell as a director and reporting insider, without detailing specific trades.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Simon Farrell

(Last) (First) (Middle)

601 GENOME WAY, SUITE 2001

(Street)

HUNTSVILLE ALABAMA 35806

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
07/22/2026

3. Issuer Name and Ticker or Trading Symbol
Serina Therapeutics, Inc. [ SER ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

No securities are beneficially owned.

	/s/ Steven Ledger, Attorney in Fact	07/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)